Many cardiac and non-cardiac drugs are associated with TdP that may constitute a significant problem because of sudden cardiac death. This study aims to present a comprehensive overview and disproportionality analysis of TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS) in order to identify new signals of TdP.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Identification of drugs associated with TdP
Timeframe: Cases reported to the FAERS database till 31/03/2019
Identification of new signals of TdP
Timeframe: Cases reported to the FAERS database till 31/03/2019